Most cancer research relies on young, healthy mice. Most cancer patients are not young. Could this disconnect between model organism and patient, which ignores the impact of the physiological realities of aging, explain why some therapies perform well in the lab but not in clinical trials? Focusing on lung cancer, a study published in Nature investigated what happens when these two realities, young and old, finally meet in the lab (1). The answers could reshape how we think about cancer research and the impact of aging on metastasis and disease progression.
The Paradox at the Heart of Lung Cancer
In a surprising contradiction, older lung cancer patients tend to have smaller primary tumors than younger patients. At the same time, they are far more likely to be diagnosed with metastatic disease where cancer has spread to other organs. How can larger tumors translate to better outcomes and smaller tumors bring worse outcomes?
Researchers at the University of Gothenburg decided to find out. Using a genetically engineered mouse model that carries the same KRAS mutation found in a large proportion of human lung adenocarcinomas, the team induced lung tumors in both young mice (2–3 months) and old mice (18–19 months) and then watched what happened. Their results solved the paradox and opened a new therapeutic door in the process.
Aging Doesn’t Slow Cancer. It Redirects It.
Old mice developed tumors that were 2.5 times smaller and grew more slowly than those in young mice. By these measures alone, aging seemed almost protective. But when the researchers looked beyond the lung, the picture changed dramatically. Aging didn’t seem to suppress cancer, just reprogram it. Despite the slower rate of tumor growth, old mice showed far higher rates of metastasis with cancer spreading to lymph nodes, kidneys, heart and other distant organs. Even more significantly, they died significantly sooner. It appears that in older mice, cancer trades bulk for mobility.
To understand why, the team isolated tumor cells from young and old mice and grew them in the lab. The two populations looked similar on the surface. They both divided at comparable rates and shared the same tissue origin, but differences emerged when the cells were stressed.
Tumor cells from the older mice were much better at surviving without a surface to attach to, a property called anoikis resistance. This is significant because detached survival is what lets cancer cells successfully circulate through the bloodstream and colonize a new organ. To measure this difference quantitatively, the researchers used the CellTiter-Glo® 2.0 Cell Viability Assay. This assay quantifies the number of living cells by detecting ATP, which is the energy source present in all metabolically active cells. Tumor cells from the older mice consistently showed higher viability under suspension conditions compared to those from younger mice.
To confirm that these cells were not just proliferating faster but also dying less, the team paired the cell viability results with apoptosis results from the Caspase-Glo® 3/7 Assay, which detects the activity of caspase-3 and caspase-7, two proteins that act as executioners of the cell death pathway (apoptosis). The tumor cells from older mice showed significantly lower caspase 3/7 activity, meaning they were actively suppressing the molecular machinery that would normally kill a detached cell. The combined results from the viability and apoptosis assays built a clear, two-sided picture: older mice’s tumor cells survive better in suspension because they suppress the normal apoptosis pathways.
A Stress Response Gone Persistent
Having solved part of the puzzle, their next step was to understand what drives this behavior at the molecular level. Through a combination of gene expression analysis (RNA sequencing) and chromatin accessibility mapping (ATAC-seq), the team identified two pathways consistently elevated in tumor cells from older mice: epithelial-to-mesenchymal transition (EMT), a process that makes cells more mobile and invasive, and the unfolded protein response (UPR), a cellular stress management system. The connection between the two pathways? A single protein, ATF4.
ATF4 is a transcription factor that sits at the center of a pathway called the integrated stress response (ISR). Normally, when a cell encounters stress (low nutrients, protein misfolding, oxygen deprivation), it briefly activates the ISR, produces ATF4 and then resolves the stress and returns to baseline. In tumor cells from older mice, that resolution step was broken. They found that aging epigenetically rewires the chromatin around the ATF4 gene, making it more accessible and easier to switch on. At the same time, the chromatin around genes that normally shut the stress response off became less accessible. The result is a cell stuck in a persistent stress state, which means ATF4 levels remain high, and the downstream program it drives stays active.
That ATF4-driven program includes upregulation of EMT markers, increased anoikis resistance and a rewired metabolism that shifts the cell away from glucose and toward glutamine as its primary fuel source. This switch gives the cells more metabolic flexibility when nutrients are scarce, which helps them survive in hostile environments such as during metastatic transit.
ATF4 Is Both Necessary and Sufficient to Drive Metastasis
One of the most compelling aspects of this study is how cleanly the role of ATF4 was established. When ATF4 was deleted or suppressed in the tumor cells from older mice, either genetically using CRISPR or pharmacologically using a compound called ISRIB, the cells lost their anoikis resistance, their EMT signature and their ability to metastasize in mice. The aging-associated metastatic phenotype essentially disappeared.
When ATF4 was overexpressed in tumor cells from younger mice, the reverse happened. Those cells, which ordinarily showed little metastatic activity in mice, acquired anoikis resistance and began forming metastatic colonies at levels comparable to those from older mice. These results suggest that ATF4 is not merely associated with aging-driven metastasis, but that it causes it.
A Druggable Vulnerability
Because ATF4 drives tumor cells toward glutamine-dependent metabolism, the researchers asked whether that dependency could be exploited therapeutically. Glutaminase inhibitors, substances that block the conversion of glutamine into metabolically usable glutamate, have had limited success in clinical trials. However, trials did not stratify patients by age. When tumor cells from older mice were exposed to a clinical-stage glutaminase inhibitor (CB-839 [telaglenastat]), they were highly sensitive to it, whereas tumor cells from younger mice were not. In mouse transplantation experiments, CB-839 treatment nearly abolished metastatic colony formation from cells from older mice without affecting primary tumor growth but had no effect on tumor cells from younger mice.
This age-selective vulnerability may explain why glutaminase inhibitors have underperformed clinically: they were being tested in populations that included younger patients whose tumors may not be ATF4-high and glutamine-dependent.
Age Is Not a Confound. It Is the Variable
This study shows a weakness in traditional research approaches for cancer and other diseases for decades where the age of the experimental model rarely matches the age of the patients. Most preclinical cancer work is done in young mice; most lung cancer patients are in their late sixties or seventies. This mismatch may have caused researchers to miss the role physiological age impacts ISR-ATF4 activation and the significant impact that this has on disease progression.
The implications of this study should go beyond lung cancer. If aging can reprogram lung tumor cells at stress response loci through epigenetic changes, it is possible that similar mechanisms that disproportionately affect older individuals may operate in other cancers. For researchers entering this field, the takeaway is direct: age is not a confounding variable to be controlled away. It is a biological variable to be studied.
Reference
- Patel, A.A., et al. (2026) Ageing promotes metastasis via activation of the integrated stress response. Nature. Published online March 11, 2026. doi:10.1038/s41586-026-10216-0. Accessed March 24, 2026.
Kelly Grooms
Latest posts by Kelly Grooms (see all)
- New Study Suggests Cancer Research Has an Age Problem - April 7, 2026
- Polar Bears, Shrinking Sea Ice and a Scientific Surprise - February 5, 2026
- From Forever Chemicals to Ancient Proteins: Five Science Stories from 2025 - January 8, 2026
